0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

JAMA Oncology | 
Invited Commentary |  ONLINE FIRST
Pieter Sonneveld, MD, PhD
JAMA Oncol. Published online July 02, 2015. doi:10.1001/jamaoncol.2015.2009

JAMA Oncology | 
Original Investigation |  Open Access ONLINE FIRST
Neha Korde, MD; Mark Roschewski, MD; Adriana Zingone, MD, PhD; et al.
JAMA Oncol. Published online July 02, 2015. doi:10.1001/jamaoncol.2015.2010
Includes: Supplemental Content

JAMA Oncology | 
Viewpoint |  ONLINE FIRST
Hagop Kantarjian, MD; Michael S. Mathisen, PharmD; Jeffrey H. Lipton, PhD, MD
JAMA Oncol. Published online July 02, 2015. doi:10.1001/jamaoncol.2015.1024
Includes: Supplemental Content

JAMA Oncology | 
Brief Report |  ONLINE FIRST
Kenar D. Jhaveri, MD; Vipulbhai Sakhiya, MBBS; Steven Fishbane, MD
JAMA Oncol. Published online June 25, 2015. doi:10.1001/jamaoncol.2015.1713

JAMA Oncology | 
Invited Commentary |  ONLINE FIRST
Daniel Sargent, PhD
JAMA Oncol. Published online June 25, 2015. doi:10.1001/jamaoncol.2015.1789

JAMA Oncology | 
Original Investigation |  ONLINE FIRST
Irfan Jawed, MD; Julia Wilkerson, MSc; Vinay Prasad, MD, MPH; et al.
JAMA Oncol. Published online June 25, 2015. doi:10.1001/jamaoncol.2015.1790
Includes: Supplemental Content

JAMA Neurology | 
Original Investigation |  FREE ONLINE FIRST
Helena Ariño, MD; Romana Höftberger, MD; Nuria Gresa-Arribas, PhD; et al.
JAMA Neurol. Published online June 22, 2015. doi:10.1001/jamaneurol.2015.0749
Includes: Supplemental Content

JAMA Internal Medicine | 
Original Investigation |  ONLINE FIRST
Vinay Prasad, MD, MPH; Chul Kim, MD, MPH; Mauricio Burotto, MD; et al.
JAMA Intern Med. Published online June 22, 2015. doi:10.1001/jamainternmed.2015.2829
Includes: Supplemental Content

JAMA Oncology | 
Invited Commentary |  ONLINE FIRST
Bart L. Scott, MD; Pamela S. Becker, MD, PhD
JAMA Oncol. Published online June 18, 2015. doi:10.1001/jamaoncol.2015.1591

JAMA Oncology | 
Original Investigation |  ONLINE FIRST
Animesh Pardanani, MD; Claire Harrison, MD; Jorge E. Cortes, MD; et al.
JAMA Oncol. Published online June 18, 2015. doi:10.1001/jamaoncol.2015.1590
Includes: Supplemental Content

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts
From The JAMA Network
JAMA Oncology
Invited Commentary  | 
Multiple Myeloma—Better Drugs Ask for More Stringent Evaluations
Pieter Sonneveld, MD, PhD
JAMA Oncology
Original Investigation  | 
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
Neha Korde, MD; Mark Roschewski, MD; Adriana Zingone, MD, PhD; et al.
JAMA Oncology
Viewpoint  | 
Having “Skin in the Game” and Allowing Cross-Border Importation of Drugs to Lower High Prices of Cancer Drugs
Hagop Kantarjian, MD; Michael S. Mathisen, PharmD; Jeffrey H. Lipton, PhD, MD
JAMA Oncology
Brief Report  | 
Nephrotoxicity of the BRAF Inhibitors Vemurafenib and Dabrafenib
Kenar D. Jhaveri, MD; Vipulbhai Sakhiya, MBBS; Steven Fishbane, MD